Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib to Delay Stage 3 Type 1 Diabetes
NCT07222137Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2026
- Primary completion
- Jul 2031
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 19
01
Overview
A Phase 3 trial of baricitinib in type 1 diabetes mellitus (T1D), sponsored by Eli Lilly and Company. Started Jan 2026; status: recruiting.
02
Drugs
baricitinib
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT07222137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07222137.